$2.720
-0.318 (-11.69%)收盤時
- High
- 2.975
- Open
- 2.960
- VWAP
- 2.73
- Vol
- 58.61K
- Mkt Cap
- —
- Low
- 2.500
- Amount
- 160.11K
- EV/EBITDA, TTM
- 0.00
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
估值指標
事件時間軸
資訊
9.508-11NewsfilterCOSCIENS Biopharma Reports Q2 2026 Financial Results
7.512-01GlobenewswireCOSCIENS Partners with Wuzhou for Exclusive Distribution of Macrilen® with €800,000 Initial Order
- 7.512-01Newsfilter
COSCIENS Partners with Wuzhou for Exclusive Distribution of Macrilen® with Initial Order of €800,000
- 9.005-30Newsfilter
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
5.005-30SeekingAlphaCOSCIENS Biopharma reconstitutes board
CSCI FAQ — answered by Alphio AI
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It operates in the Healthcare sector.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。